ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA "Boxed Warning" A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association

被引：155

作者：

Holmes, David R., Jr.

Dehmer, Gregory J.

Kaul, Sanjay

Leifer, Dana

O'Gara, Patrick T.

Stein, C. Michael

机构：

来源：

CIRCULATION | 2010年 / 122卷 / 05期

关键词：

AHA Scientific Statements; clopidogrel; FDA boxed warning; CYP2C19; PERCUTANEOUS CORONARY INTERVENTION; MAINTENANCE-DOSE CLOPIDOGREL; ASPIRIN-TREATED PATIENTS; PRASUGREL ACHIEVES GREATER; DUAL ANTIPLATELET THERAPY; PLATELET INHIBITION; DOUBLE-BLIND; MYOCARDIAL-INFARCTION; CARE ASSAY; ATHEROTHROMBOTIC EVENTS;

D O I：

10.1161/CIR.0b013e3181ee08ed

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：537 / 557

页数：21

共 73 条

[41] Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction [J].

Matetzky, S ;

Shenkman, B ;

Guetta, V ;

Schechter, M ;

Bienart, R ;

Goldenberg, I ;

Novikov, I ;

Pres, H ;

Savion, N ;

Varon, D ;

Hod, H .

CIRCULATION, 2004, 109 (25) :3171-3175

[42] Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes [J].

Mega, Jessica L. ;

Close, Sandra L. ;

Wiviott, Stephen D. ;

Shen, Lei ;

Hockett, Richard D. ;

Brandt, John T. ;

Walker, Joseph R. ;

Antman, Elliott M. ;

Macias, William L. ;

Braunwald, Eugene ;

Sabatine, Marc S. .

CIRCULATION, 2009, 119 (19) :2553-U44

[43] Cytochrome P-450 Polymorphisms and Response to Clopidogrel. [J].

Mega, Jessica L. ;

Close, Sandra L. ;

Wiviott, Stephen D. ;

Shen, Lei ;

Hockett, Richard D. ;

Brandt, John T. ;

Walker, Joseph R. ;

Antman, Elliott M. ;

Macias, William ;

Braunwald, Eugene ;

Sabatine, Marc S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (04) :354-362

[44]

MEGA JL, 2010, J AM COLL CARDIOL S, V55, pA113

[45]

MEGA JL, 2010, CLOPIDOGREL GENETIC

[46]

MEHTA SR, 2009, COMMUNICATION AUG

[47] Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial [J].

Michelson, Alan D. ;

Frelinger, Andrew L., III ;

Braunwald, Eugene ;

Downey, William E. ;

Angiolillo, Dominick J. ;

Xenopoulos, Nicholas P. ;

Jakubowski, Joseph A. ;

Li, Youfu ;

Murphy, Sabina A. ;

Qin, Jie ;

McCabe, Carolyn H. ;

Antman, Elliott M. ;

Wiviott, Stephen D. .

EUROPEAN HEART JOURNAL, 2009, 30 (14) :1753-1763

[48] A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes - The ALBION (assessment of the best loading dose of clopidogrel to blunt platelet activation, inflammation and ongoing necrosis) trial [J].

Montalescot, Gilles ;

Sideris, Georges ;

Meuleman, Catherine ;

Bal-dit-Sollier, Claire ;

Lellouche, Nicolas ;

Steg, Ph. Gabriel ;

Slama, Michel ;

Milleron, Olivier ;

Collet, Jean-Philippe ;

Henry, Patrick ;

Beygui, Farzin ;

Drouet, Ludovic .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 48 (05) :931-938

[49] Black box 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk [J].

Murphy, S ;

Roberts, R .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 117 (01) :34-39

[50] Can We Override Clopidogrel Resistance? [J].

Pena, Ana ;

Collet, Jean-Philippe ;

Hulot, Jean-Sebastien ;

Silvain, Johanne ;

Barthelemy, Olivier ;

Beygui, Farzin ;

Funck-Brentano, Christian ;

Montalescot, Gilles .

CIRCULATION, 2009, 119 (21) :2854-2857

← 1 2 3 4 5 6 7 8 →